For the last several months, we’ve talked to many people within the
diabetes community and asked, “What more can we do?” based on the
healthcare system Americans rely on today. These people face different
challenges and situations and one solution can’t cover them all. While
we continue to
work with others in the US healthcare system for a longer-term
solution, we feel the sense of urgency and anger from the community
and want to do more both for those who have insurance and those who do not.
So, in addition to Novo Nordisk’s current affordability options on
NovoCare.com—including our Patient Assistance Programs that can offer
free medicines to eligible patients, Novo Nordisk human insulin which
has been available for $25/vial at Walmart and recently expanded to
CVS Health and ESI, and our co-pay savings cards—Novo Nordisk will
offer two additional options on January 2, 2020:
A $99.00 Cash Card Program for Analog Insulins: As part of
this program, people with diabetes can purchase up to three vials or
two packs of FlexPen®/FlexTouch® pens of any combination of Novo
Nordisk analog insulins (3000 – 3800 Units total depending on the
brands) for a flat cost of $99.00. To put this in perspective, this
amount of product should cover most patients’ monthly insulin needs.
This program is being made available from the Novo Nordisk US
affiliate Novo Nordisk Inc. (NNI)
Follow-On Insulin Brands (also known as an authorized
generic): Follow-on brand versions of Novo Nordisk’s most-widely
prescribed short-acting analog insulins will be made available from
the newly established Novo Nordisk US affiliate Novo Nordisk Pharma
Inc. (NNPI) at a 50 percent discount compared to the current list
price of the branded versions.
More details are found in our press
release and more specific details will be available at the time
these offerings are launched. We believe these offerings represent
helpful additions to our NovoCare® affordability program,
especially for people with diabetes in high-deductible health plans or
Although we hope this is a meaningful step, we recognize that it’s
not the answer for everyone. We’ll continue to work toward longer-term
reform and making it easier for people who need our help to get it.
For instance, we support the recent IRS ruling that classifies
diabetes medications as preventive care. This has the potential to
help so many people with diabetes. We are actively requesting that
insurance plan decision makers participate in this new rule.
In the meantime, anyone who needs help affording our medicines
should visit NovoCare.com for information about our Patient Assistance
Programs, co-pay cards, and more, or call our Customer Care team at 1.800.727.6500.